## AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

# Listing of Claims:

(Previously Presented) A sulfonamide compound according to formula I

$$\begin{array}{c|c} \operatorname{Ar}^{1} & \operatorname{N} & (\operatorname{CH}_{2})_{\operatorname{n}} & \operatorname{Ar}^{2} & \operatorname{SO}_{2} & \operatorname{Y} \\ & \operatorname{X} & \operatorname{R}^{1} & \end{array}$$

1

with its geometrical isomers, in an optically active form as enantiomers, diastereomers, as well as in the form of racemates, as well as pharmaceutically acceptable salts thereof, wherein

Ar¹ is selected from the group consisting of phenyl, thienyl, furanyl, pyridyl, and optionally substituted by substituted or unsubstituted  $C_1$ - $C_6$  alkyl, substituted or unsubstituted  $C_2$ - $C_6$  alkenyl, substituted  $C_2$ - $C_6$  alkenyl, substituted or unsubstituted  $C_2$ - $C_6$  alkenyl, amino, acylamino, aminocarbonyl,  $C_1$ - $C_6$  alkoxycarbonyl, aryl, carboxyl, cyano, halo, hydroxy, nitro, sulfonyl, sulfoxy, acyloxy,  $C_1$ - $C_6$  thioalkoxy;

 ${\rm Ar}^2$  is selected from the group consisting of thienyl, furanyl, and pyridyl;

X is 0 or S;

 $R^1$  is hydrogen or a  $C_1$ - $C_6$ -alkyl group, or  $R^1$  forms a substituted or unsubstituted 5-6-membered saturated or unsaturated ring with  $Ar^4$ ;

n is an integer from 0 to 5;
Y is a piperidino group of the formula

## wherein

 $L^1$  and  $L^2$  are independently selected from the group consisting of H, substituted or unsubstituted  $C_1$ - $C_6$ -alkyl, substituted or unsubstituted or unsubstituted or unsubstituted or unsubstituted or unsubstituted  $C_2$ - $C_6$ -alkynyl, and substituted or unsubstituted cyclic  $C_4$ - $C_8$ -alkyl optionally containing 1-3 heteroatoms and optionally fused with aryl or heteroaryl; or  $L^1$  and  $L^2$  are independently selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, aryl- $C_1$ - $C_6$ -alkyl, heteroaryl- $C_1$ - $C_6$ -alkyl, -C(0)- $0R^3$ , -C(0)- $R^3$ , -C(0)- $R^3$ , - $R^3$ , - $R^3$ , - $R^3$ - $R^$ 

with  $R^3$  and  $R^{3'}$  being substituents independently selected from the group consisting of H, substituted or unsubstituted  $C_1$ - $C_5$ -alkyl, substituted or unsubstituted  $C_2$ - $C_5$ -alkenyl, substituted or unsubstituted aryl, substituted or

unsubstituted heteroaryl, substituted or unsubstituted aryl- $C_1$ - $C_6$ -alkyl, and substituted or unsubstituted heteroaryl- $C_1$ - $C_6$ -alkyl;

said aryl or heteroaryl groups being optionally substituted  $C_1$ - $C_6$ -alkyl,  $C_1$ - $C_6$ -alkoxy,  $C_2$ - $C_6$ -alkenyl,  $C_2$ - $C_6$ -alkynyl, amino, acylamino, aminocarbonyl,  $C_1$ - $C_6$ -alkoxycarbonyl, aryl, carboxyl, cyano, halogen, hydroxy, nitro, sulfonyl, sulfoxy or  $C_1$ - $C_6$ -thioalkoxy; and

 $R^6$  is selected from the group consisting of hydrogen, substituted or unsubstituted  $C_1\text{-}C_6\text{-alkyl},$  substituted or unsubstituted  $C_1\text{-}C_6\text{-alkoxy},$  OH, halogen, nitro, cyano, sulfonyl, and oxo (=0); and

n' is an integer from 0 to 4;

with the provise that if  $Ar^1$  is 4-chlorophenyl, then X is O,  $R^1$  is H,  $Ar^2$  is thienyl, and Y is not para-substituted by 2-hydroxyethyl;

wherein the term "substituted" means that the group that is substituted is substituted with from its 5 substituents, said substituents being a group selected from the group consisting of C<sub>1</sub>-C<sub>6</sub> alkyl; C<sub>1</sub>-C<sub>5</sub> alkyl aryl; C<sub>1</sub>-C<sub>6</sub> alkyl heteroaryl; C<sub>2</sub>-C<sub>6</sub> alkenyl; C<sub>2</sub>-C<sub>6</sub> alkynyl; primary, secondary or tertiary amino groups; quaternary ammonium groups; acyl; acyloxy; acylamino; aminocarbonyl; alkoxycarbonyl; aryl; heteroaryl; carboxyl; cyano; halogen;

hydroxyl; mercapto; nitro; sulfoxy; sulfonyl; alkoxy, thioalkoxy; and trihalomethyl.

(Currently amended) A composition comprising a sulfonamide compound according to formula I

with its geometrical isomers, in an optically active form as enantiomers, diastereomers, as well as in the form of racemates, as well as pharmaceutically acceptable salts thereof, wherein

X is O or S:

 $\mbox{Ar}^1$  and  $\mbox{Ar}^2$  are a substituted or unsubstituted aryl or heteroaryl group;

 $R^1$  is hydrogen or a  $C_1\text{--}C_6\text{--alkyl}$  group, or  $R^1$  forms a substituted or unsubstituted 5-6-membered saturated or unsaturated ring with  $Ar^2,$ 

n is an integer from 0 to 5;

Y is a piperidino group of the formula

wherein

 $L^1$  and  $L^2$  are independently selected from the group consisting of H, substituted or unsubstituted  $C_1$ - $C_6$ -alkyl, substituted or unsubstituted  $C_2$ - $C_6$ -alkenyl, substituted or unsubstituted  $C_2$ - $C_6$ -alkynyl, and substituted or unsubstituted cyclic  $C_4$ - $C_6$ -alkyl optionally containing 1-3 heteroatoms and optionally fused with aryl or heteroaryl; or  $L^1$  and  $L^2$  are independently selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, aryl- $C_1$ - $C_6$ -alkyl, heteroaryl- $C_1$ - $C_6$ -alkyl, -C(0)- $OR^3$ , -C(0)- $OR^3$ , -C(0)- $OR^3$ , -C(0)- $OR^3$ , - $OR^3$ -OR

with  $R^3$  and  $R^{2'}$  being substituents independently selected from the group consisting of H, substituted or unsubstituted  $C_1$ - $C_6$ -alkyl, substituted or unsubstituted  $C_2$ - $C_6$ -alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted aryl- $C_1$ - $C_6$ -alkyl, and substituted or unsubstituted heteroaryl- $C_1$ - $C_6$ -alkyl,

said aryl or heteroaryl groups being optionally substituted  $C_1$ - $C_6$ -alkyl,  $C_1$ - $C_6$ -alkoxy,  $C_2$ - $C_6$ -alkenyl,  $C_2$ - $C_6$ -alkynyl, amino, acylamino, aminocarbonyl,  $C_1$ - $C_6$ -alkoxycarbonyl, aryl, carboxyl, cyano, halogen, hydroxy, nitro, sulfonyl, sulfoxy, or  $C_1$ - $C_6$ -thioalkoxy; and

 $R^6$  is selected from the group consisting of hydrogen, substituted or unsubstituted  $C_1\text{--}C_6\text{--alkyl},$  substituted or unsubstituted  $C_1\text{--}C_6\text{--alkoxy},$  OH, halogen, nitro, cyano, sulfonyl, and oxo (=0); and

n' is an integer from 0 to 4;

with the proviso that if Y is substituted at the £-position of the piperidino—nitrogen by a benzo[5, 6] eyelohepta[1, 2b]pyridine, or a benzo[5, 6] eyelohepta[1, 2b]pyridine, while Are is thienyl, X is oxygen, Ri is hydrogen and n is 1, Are shall not be a phenyl group;

and a pharmaceutically acceptable carrier.

### 3-4. (Cancelled)

5. (Previously Presented) A sulfonamide compound according to claim 1, wherein  $Ar^1$  is selected from the group consisting of phenyl, thienyl, furyl, pyridyl, and optionally substituted by  $C_1-C_6$ -alkyl,  $C_1-C_6$ -alkoxy,  $C_2-C_6$ -alkenyl,  $C_2-C_6$ -alkynyl, amino, acylamino, aminocarbonyl,  $C_1-C_6$ -alkoxycarbonyl, aryl, carboxyl, cyano, halogen, hydroxy, nitro, sulfonyl and  $C_1-C_6$ -thioalkoxy.

- 7 -

6. (Previously Presented) A sulfonamide compound according to claim 5, wherein Ar<sup>1</sup> is an unsubstituted or substituted phenyl.

- 7. (Previously Presented) A sulfonamide compound according to claim 5, wherein  ${\tt Ar}^2$  is thienyl or furanyl group.
- 8. (Previously Presented) A sulfonamide compound according to claim 1, wherein  $Ar^{1}$  is selected from the group consisting of a 4-chlorophenyl, nitrophenyl, hydroxyphenyl, alkoxy phenyl, pyridyl, 3,4,-dihydroxyphenyl, and X is 0,  $R^{1}$  is hydrogen, n is 1,  $Ar^{2}$  is thienyl or furanyl.
- (Previously Presented) A sulfonamide compound according to claim 8, wherein Y is



 $(R^6)$  is selected from the group consisting of hydrogen, substituted or unsubstituted  $C_1$ - $C_6$  alkyl, substituted or unsubstituted  $C_1$ - $C_6$  alkoxy, OH, halogen, nitro, cyano, sulfonyl, and oxo; n' is an integer of from 0 to 4; and

wherein  $L^1$  and  $L^2$  are independently selected from each other from the group consisting of H, substituted or unsubstituted  $C_1$ - $C_6$ - alkyl, substituted or unsubstituted  $C_2$ - $C_6$  alkenyl; or  $L^1$  and  $L^2$  are independently selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted or unsubstituted or unsubstituted cyclic  $C_4$ - $C_8$  alkyl optionally containing 1-3 heteroatoms and optionally fused with aryl or heteroaryl, aryl- $C_1$ - $C_4$  alkyl, heteroaryl- $C_1$ - $C_4$  alkyl, -C(O)- $OR^3$ , -C(O)- $R^3$ , -C(O)- $NR^3$ ' $R^3$ , -  $NR^3$ ' $R^3$ , - $NR^3$ 'C(O)R $^3$ , - $NR^3$ R $^3$ ', and - $NC_2$ NR $^3$ R $^3$ ';

with  $R^3$  and  $R^{3'}$  being substituents independently selected from the group consisting of H, substituted or unsubstituted  $C_1$ - $C_4$  alkyl, substituted or unsubstituted  $C_2$ - $C_6$  alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aryl- $C_1$ - $C_4$ -alkyl, substituted or unsubstituted heteroaryl- $C_1$ - $C_6$ -alkyl;

said aryl or heteroaryl groups being optionally substituted with a member selected from the group consisting of  $C_1$ - $C_6$ -alkyl,  $C_1$ - $C_6$ -alkoxy,  $C_2$ - $C_6$ -alkenyl,  $C_2$ - $C_6$ -alkynyl, amino, acylamino, aminocarbonyl,  $C_1$ - $C_6$ -alkoxycarbonyl, aryl, carboxyl, cyano, halogen, hydroxy, nitro, sulfonyl, sulfoxy and  $C_1$ - $C_6$ -thioalkoxy.

10. (Previously Presented) A sulfonamide compound according to claim 9, wherein  $\mathbb{R}^6$  is H,  $L^2$  is H,  $L^1$  is a 5-membered cyclic group containing 3 heteroatoms or  $L^1$  is  $-C(0)-\mathbb{R}^3$ , or  $-NH\mathbb{R}^3$ ;

### wherein Y is



n' is an integer of from 0 to 4;

with  $R^3$  being a substituent selected from the group comprising or consisting of  $C_1\text{-}C_4\text{-}alkyl$ , aryl, heteroaryl,  $aryl\text{-}C_1\text{-}C_4\text{-}alkyl$  and heteroaryl- $C_1\text{-}C_6\text{-}alkyl$ ;

said aryl or heteroaryl groups being optionally substituted by halogen, hydroxy, nitro, or sulfonyl.

11. (Currently amended) A sulfonamide compound according to claim 1, selected from the group consisting of:

4-chloro-N-{5-[4-(3-trifluoromethanesulfonylphenylamino)-piperidine-1-sulfonyl]-thiophen-2-ylmethyl}benzamide:

 $\label{lem:decomposition} $$4-$ chloro-N-[(5-{[4-(4-fluorobenzoy1)piperidin-1-y1]sulfony1}thien-2-y1)methyl] benzamide;$ 

```
Appln. No. 10/070,954
Amdt. dated June 3, 2010
Reply to Advisory Action of March 10, 2010
```

```
4-chloro-N-({5-[(4-hydroxy-4-phenylpiperidin-1-
yl) sulfonyl] thien-2-yl}methyl) benzamide;
          N-({5-[(4-benzoylpiperidin-1-vl)sulfonvl]thien-2-
yl \methyl) -4-chlorobenzamide;
          4-chloro-N-[(5-{[4-(2-oxo-2.3-dihvdro-1H-
benzimidazol-1-yl)piperidin-1-yl]sulfonyl}thien-2-
v1) methyl benzamide;
          N-({5-[(4-benzylpiperidin-1-yl)sulfonyl]thien-2-
yl}methyl)-4-chlorobenzamide;
          4-chloro-N-[(5-{[4-(2,4-difluorobenzoyl)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]benzamide;
          4-chloro-N-{[5-(piperidin-1-ylsulfonyl)thien-2-
yl]methyl}benzamide;
          4-chloro-N-{[5-({3-hydroxy-4-[3-
(trifluoromethyl)phenyl|piperidin-1-vl}sulfonyl)thien-2-
yl]methyl}benzamide;
          4-chloro-N-({5-[(4-hydroxypiperidin-1-
yl) sulfonyl] thien-2-yl}methyl) benzamide:
          N-({5-[(4-benzyl-4-hydroxypiperidin-1-
v1) sulfonyl] thien-2-v1}methv1) -4-chlorobenzamide:
          N-{ [5-({4-[(2-tert-butvl-1H-indol-5-
yl)amino]piperidin-1-yl}sulfonyl)thien-2-yl]methyl}-4-
chlorobenzamide:
```

```
Appln. No. 10/070,954
Amdt. dated June 3, 2010
Reply to Advisory Action of March 10, 2010
```

```
4-chloro-N-{[5-({4-[(phenylacetyl)aminolpiperidin-1-
yl}sulfonyl)thien-2-yl]methyl}benzamide;
          N-[(5-{[4-(2H-1,2,3-benzotriazo1-2-y1)piperidin-1-
vl]sulfonyl}thien-2-vl)methvl]-4-chlorobenzamide:
          4-chloro-N-[(5-{[4-(4-chlorobenzoyl)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]benzamide;
          N-{[5-({4-[benzyl(methyl)amino]piperidin-1-
yl}sulfonyl)thien-2-yl]methyl}-4-chlorobenzamide;
          4-chloro-N-{[5-({4-[3-(2,4-dichlorophenyl)-1H-
pyrazol-5-vl|piperidin-1-vl}sulfonvl)thien-2-
yl]methyl}benzamide;
          4 chloro N [(5 [[4-(5-thien-2-yl-1H-pyrazol-3-
yl)piperidin 1 yl]sulfonyl}thien 2 vl)methyllbenzamide:
          4-chloro-N-[(5-{[4-(2,3,4,5,6-
pentamethylbenzoyl)piperidin-1-vl]sulfonyl}thien-2-
yl) methyl]benzamide;
          4-chloro-N-{[5-({4-[5-(4-methoxyphenyl)-1H-pyrazol-
3-yl]piperidin-1-yl}sulfonyl)thien-2-yl]methyl}benzamide;
          N-({5-[(4-anilinopiperidin-1-v1)sulfonvl]thien-2-
vl}methvl)-4-chlorobenzamide:
          4-chloro-N-[(5-{[4-(2-phenylethyl)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]benzamide;
          N-[(5-{[4-(1H-1,2,3-benzotriazol-1-vl)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;
```

2-{1-[(5-{[(4-chlorobenzoyl)amino]methyl}thien-2-yl)sulfonyl]piperidin-4-yl}-2H-1,2,3-benzotriazole-5-carboxylic acid;

methyl 1-{1-[(5-{[(4-

chlorobenzoy1) amino] methyl}thien-2-yl) sulfonyl]piperidin-4yl}-1H-1,2,3-benzotriazole-5-carboxylate;

methyl 1-{1-[(5-{[(4-

chlorobenzoy1)amino]methyl}thien-2-yl)sulfonyl]piperidin-4yl}-1H-1,2,3-benzotriazole-6-carboxylate:

methyl 2-{1-[(5-{[(4-

chlorobenzoy1)amino]methyl}thien-2-yl)sulfonyl]piperidin-4yl}-2H-1,2,3-benzotriazole-5-carboxylate;

4-chloro-N-[(5-{[4-(6-chloro-1H-1,2,3-benzotriazol-1-yl)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;

 $\hbox{$4$-chloro-N-{ [5-(\{4-[5-(trifluoromethyl)-1H-1,2,3-1H-1,3-1H-$ 

benzotriazol-1-yl]piperidin-1-yl}sulfonyl)thien-2yl]methyl}benzamide;

1-{1-[(5-{[(4-chlorobenzoyl)amino]methyl}thien-2yl)sulfonyl]piperidin-4-yl}-1H-1,2,3-benzotriazole-5carboxylic acid;

- 13 -

```
Appln. No. 10/070,954
Amdt. dated June 3, 2010
Reply to Advisory Action of March 10, 2010
```

```
1-{1-[(5-{[(4-chlorobenzoyl)amino]methyl}thien-2-
yl)sulfonyl]piperidin-4-yl}-1H-1,2,3-benzotriazole-6-
carboxvlic acid:
          N-[(5-{[4-(2-amino-9H-purin-9-vl)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;
          4-chloro-N-[(5-{[4-(9H-purin-9-yl)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]benzamide:
          N-[(5-{[4-(6-amino-9H-purin-9-yl)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;
          4-chloro-N-({5-[(4-{6-nitro-1H-benzimidazol-1-
yl}piperidin-1-yl)sulfonyl]thien-2-yl}methyl)benzamide;
          4-chloro-N-({5-[(4-{5-nitro-1H-benzimidazol-1-
yl}piperidin-1-yl)sulfonyl]thien-2-yl}methyl)benzamide;
          4-chloro-N-[(5-{[4-(2H-1,2,3-triazol-2-yl)piperidin-
1-yl]sulfonyl}thien-2-yl)methyl]benzamide;
          N-[(5-{[4-(1H-benzimidazol-1-vl)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;
          4-chloro-N-{[5-({4-[3-propylanilino]piperidin-1-
yl sulfonyl) thien-2-yl methyl benzamide;
          4-chloro-N-{[5-({4-[3-
(dimethylamino) anilino] piperidin-1-yl sulfonyl) thien-2-
yl]methyl}benzamide;
          methyl 3-({1-[(5-{[(4-chlorobenzov])amino]-
methyl}thien-2-yl)sulfonyl]piperidin-4-yl}amino)-benzoate;
```

```
Appln. No. 10/070,954
Amdt. dated June 3, 2010
Reply to Advisory Action of March 10, 2010
          4-chloro-N-{[5-({4-[3-
(methylsulfanyl)anilinolpiperidin-1-vl}sulfonyl)thjen-2-
vllmethvllbenzamide:
          4-chloro-N-({5-[(4-{3-nitroanilino}piperidin-1-
yl) sulfonyl] thien-2-yl}methyl) benzamide;
          4-chloro-N-[(5-{[4-(2-methoxyanilino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]benzamide;
          3-({1-[(5-{[(4-chlorobenzovl)amino]methvl}thien-2-
yl) sulfonyl] piperidin-4-yl}amino) benzamide;
          4-chloro-N-({5-[(4-{2-nitro-4-
[(trifluoromethyl)sulfonyl]anilino}piperidin-1-
vl) sulfonvl|thien-2-vl}methvl)benzamide;
          4-chloro-N-[(5-{[4-(4-chloroanilino)piperidin-1-
vl|sulfonvl}thien-2-vl)methvl|benzamide:
          4-chloro-N-({5-[(4-{4-
[(trifluoromethyl)sulfonyl]anilino}piperidin-1-
yl) sulfonyl] thien-2-yl}methyl) benzamide;
          4-chloro-N-({5-[(4-{2-nitroanilino}piperidin-1-
yl) sulfonyl] thien-2-yl }methyl) benzamide;
          N-{[5-({4-[4-(aminocarbonyl)anilino]piperidin-1-
yl}sulfonyl)thien-2-yl]methyl}-4-chlorobenzamide;
```

- 15 -

N-[(5-{[4-(3-chloroanilino)piperidin-1-

yl]sulfonyl}thien-2-yl)methyl]-3-nitrobenzamide;

```
Appln. No. 10/070.954
Amdt, dated June 3, 2010
Reply to Advisory Action of March 10, 2010
          4-chloro-N-[(5-{[4-(3-chloroanilino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]benzamide;
          4-chloro-N~[(5-{[4-(3-methoxyanilino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]benzamide;
          4-chloro-N-{[5-({4-[3-
(methylsulfonyl) anilino] piperidin-1-yl } sulfonyl) thien-2-
yl]methyl}benzamide;
          N-[(5-{[4-(2-aminoanilino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;
          4-chloro-N-[(5-{[4-(2-hydroxyanilino)piperidin-1-
vl]sulfonvl}thien-2-vl)methvl]benzamide:
          4-chloro-N-[(5-{[4-(4-hydroxyanilino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]benzamide;
          4-chloro-N-[(5-{[4-(3-toluidino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]benzamide;
          N-[(5-{[4-(3-tert-butylanilino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;
          4-chloro-N-[(5-{[4-(2-propylanilino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]benzamide;
          4-chloro-N-{[5-({4-[(2,2-dioxido-1,3-dihydro-2-
benzothien-5-vl)amino|piperidin 1-vl}sulfonvl)thicn-2-
vllmethvl}benzamide:
          4 chloro N [(5 [[4 (2,3 dihydro 1H inden 5
```

ylamino) piperidin 1-yl|sulfonyl|thien-2-yl) methyl|benzamide:

```
Appln. No. 10/070,954
Amdt. dated June 3, 2010
Reply to Advisory Action of March 10, 2010
```

```
4-chloro-N-[(5-{[4-(4-propylanilino)piperidin-1-
vllsulfonvl}thien-2-vl)methvllbenzamide:
          4-chloro-N-[(5-{[4-({3-nitropyridin-2-
yl}amino)piperidin-1-yl]sulfonyl}thien-2-yl)methyl]benzamide;
          N-{ [5-({4-[(3-aminopyridin-2-yl)amino]piperidin-1-
yl}sulfonyl)thien-2-yl]methyl}-4-chlorobenzamide;
          4-chloro-N-[(5-{[4-(pyrimidin-2-ylamino)piperidin-1-
yl]sulfonyl}thien-2-vl)methyl|benzamide;
          4-chloro-N-({5-[(4-{[4-(trifluoromethyl)pyrimidin-2-
yl]amino}piperidin-1-yl)sulfonyl]thien-2-yl}methyl)benzamide;
          4-chloro-N-[(5-{[4-(3-ethylanilino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]benzamide;
          4 chloro N [(5 {[4 (5,6,7,8 tetrahydronaphthalen 1
ylamino) piperidin-1 yl] sulfonyl thien-2-yl) methyl benzamide:
          4-chloro-N-[(5-{[4-(quinolin-5-ylamino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]benzamide;
          4-chloro-N-[(5-{[4-(quinolin-8-ylamino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]benzamide;
          4-nitro-N-({5-[(4-{3-
[(trifluoromethyl)sulfonyl]anilino}piperidin-1-
yl) sulfonyl] thien-2-yl methyl) benzamide;
          N-[(5-{[4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-
vl]sulfonvl}thien-2-vl)methvl]-3-nitrobenzamide:
```

```
Appln. No. 10/070,954
Amdt. dated June 3, 2010
Reply to Advisory Action of March 10, 2010
```

```
N-[(5-{[4-(2,4-difluorobenzoyl)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]-4-nitrobenzamide;
          N-[(5-{[4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-
vllsulfonvl}thien-2-vl)methvll-4-nitrobenzamide:
          3-nitro-N-[(5-{[4-(3-methoxyanilino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]benzamide;
          N-{[5-({4-[3-(dimethylamino)anilino]piperidin-1-
yl}sulfonyl)thien-2-yl]methyl}-3-nitrobenzamide;
          3-nitro-N-{[5-({4-[3-
(methylsulfonyl) anilino] piperidin-1-yl}sulfonyl) thien-2-
yl]methyl}benzamide;
          3-nitro-N-{[5-({4-[3-
(methylsulfanyl) anilino| piperidin-1-vl}sulfonyl) thien-2-
yl]methyl}benzamide;
          methyl 3-{[1-({5-[({3-nitrobenzoyl}amino)methyl]-
thien-2-vl}sulfonvl)-piperidin-4-vl]amino}benzoate:
          N-{[5-({4-[3-(aminocarbonyl)anilino]piperidin-1-
yl}sulfonyl)thien-2-yl]methyl}-3-nitrobenzamide;
          3-nitro-N-({5-[(4-{3-nitroanilino}piperidin-1-
yl) sulfonyl] thien-2-yl}methyl) benzamide;
          3-nitro-N-[(5-{[4-(2-methoxyanilino)piperidin-1-
yl] sulfonyl}thien-2-yl) methyl] benzamide;
          3-nitro-N-({5-[(4-{2-nitroanilino}piperidin-1-
vl) sulfonyl] thien-2-yl}methyl) benzamide;
```

```
Appln. No. 10/070,954
Amdt. dated June 3, 2010
Reply to Advisory Action of March 10, 2010
```

```
N-[(5-{[4-(4-chloroanilino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]-3-nitrobenzamide:
          3-nitro-N-({5-[(4-{4-
[(trifluoromethyl)sulfonyl]anilino}piperidin-1-
v1) sulfonv1] thien-2-v1}methv1) benzamide:
          N-{[5-({4-[4-(aminocarbonyl)anilino]piperidin-1-
yl}sulfonyl)thien-2-yl]methyl}-3-nitrobenzamide;
          N-[(5-{[4-(3-propylanilino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]-3-nitrobenzamide;
          N-[(5-{[4-(3-chloroanilino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]-4-nitrobenzamide;
          4-nitro-N-[(5-{[4-(3-methoxyanilino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]benzamide;
          N-{[5-({4-[3-(dimethylamino)anilino]piperidin-1-
yl}sulfonyl)thien-2-yl]methyl}-4-nitrobenzamide:
          4-nitro-N-[(5-{(4-(3-propylanilino)piperidin-1-
vl]sulfonyl}thien-2-vl)methvl]benzamide;
          4-nitro-N-{[5-({4-[3-
(methylsulfonyl) anilino|piperidin-1-vl}sulfonyl) thien-2-
yl]methyl}benzamide;
          4-nitro-N-{[5-({4-[3-
(methylsulfanyl)anilino]piperidin-1-yl}sulfonyl)thien-2-
yl]methyl}benzamide;
```

methyl 3-{[1-({5-[({4-nitrobenzoyl}amino)methyl]thien-2-yl}sulfonyl)piperidin-4-yl]amino}benzoate; 3-{[1-({5-[({4-nitrobenzoyl}amino)methyl]thien-2yl}sulfonyl)piperidin-4-yllamino}benzamide: 4-nitro-N-({5-[(4-{3-nitroanilino}piperidin-1yl) sulfonyl] thien-2-yl}methyl) benzamide; 4-nitro-N-[(5-{[4-(2-methoxyanilino)piperidin-1vl|sulfonvl}thien-2-vl)methvl|benzamide: 4-nitro-N-({5-[(4-{2-nitroanilino}piperidin-1yl)sulfonyl]thien-2-yl}methyl)benzamide; N-[(5-{[4-(4-chloroanilino)piperidin-1yl]sulfonyl}thien-2-yl)methyl]-4-nitrobenzamide; 4-nitro-N-({5-f(4-{4-[(trifluoromethyl)sulfonyl]anilino}piperidin-1yl) sulfonyl] thien-2-yl}methyl) benzamide; N-{[5-({4-[4-(aminocarbonvl)anilino]piperidin-1yl}sulfonyl)thien-2-yl]methyl}-4-nitrobenzamide; N-({5-[(4-anilinopiperidin-1-yl)sulfonyl]thien-2yl}methyl)-3-nitrobenzamide; N-({5-[(4-anilinopiperidin-1-yl)sulfonyl]thien-2vl}methyl) -4~nitrobenzamide; 3-nitro-N-[(5-{[4-({3-nitropyridin-2yl amino) piperidin-1-yl] sulfonyl thien-2-yl) methyl] benzamide;

```
-N-{{5-({4-[(2,2-dioxido-1,3-dihydro-2-benzothien-5-
yl)amino|piperidin-1-yl}sulfonyl)thien-2-yl]methyl}-3-
nitrobenzamide:
          N [(5-[4-(2,3 dihydro-1H-inden-5-ylamino)piperidin-
1-yl]sulfonyl|thien-2-yl)methyl]-3-nitrobenzamide;
          3-nitro-N-[(5-{[4-(2-propylanilino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]benzamide;
          3-nitro-N-[(5-{[4-(4-propylanilino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]benzamide;
          N-[(5-{[4-(3-tert-butylanilino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]-3-nitrobenzamide;
          3-nitro-N-[(5-{[4-(2-phenylethyl)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl|benzamide;
          4-nitro-N-[(5-{[4-(pyrimidin-2-ylamino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]benzamide;
          N-{[5-({4-[(3-aminopyridin-2-yl)amino]piperidin-1-
yl}sulfonyl)thien-2-yl]methyl}-4-nitrobenzamide;
          4-nitro-N-[(5-{[4-({3-nitropyridin-2-
yl amino) piperidin-1-yl] sulfonyl thien-2-yl) methyl benzamide;
          N-[(5-[[4-(2-3-dihydro-1H-inden-5-vlamino)piperidin-
1-vl]sulfonyl}thien-2-yl)methyl]-4-nitrobenzamide;
          4-nitro-N-[(5-{[4-(2-propvlanilino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]benzamide;
```

```
Appln. No. 10/070,954
Amdt. dated June 3, 2010
Reply to Advisory Action of March 10, 2010
```

```
4-nitro-N-[(5-{[4-(4-propylanilino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]benzamide;
         N-[(5-{[4-(3-tert-butylanilino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]-4-nitrobenzamide;
          4-nitro-N-[(5-{[4-(2-phenylethyl)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]benzamide;
          N-[(5-{[4-(2-aminoanilino)piperidin-1-
yl]sulfonyl}thien-2-vl)methvl]-3-nitrobenzamide;
          3-nitro-N-[(5-{[4-(pyrimidin-2-ylamino)piperidin-1-
yl]sulfonyl}thien-2-vl)methvl]benzamide:
         N-{[5-({4-[(3-aminopyridin-2-yl)amino]piperidin-1-
yl}sulfonyl)thien-2-yl]methyl}-3-nitrobenzamide;
          N-({5-[(4-{2-nitro-4-
[(trifluoromethyl)sulfonyl]anilino}piperidin-1-
yl) sulfonyl] thien-2-yl \methyl) -3-methoxybenzamide;
          N-[(5-{[4-(3-ethylanilino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]-3-nitrobenzamide;
          3 nitro N [(5-[4-(5,6,7,8-tetrahydronaphthalen-1-
ylamino) piperidin-1-yl] sulfonyl} thien-2-yl) methyl] benzamide;
          N-[(5-{[4-(2,4-difluorobenzoyl)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]-3-nitrobenzamide;
          N-[(5-{[4-(2,4-difluorobenzoyl)piperidin-1-
v1]sulfonv1}thien-2-v1)methv1]-3-methoxybenzamide:
```

```
Appln. No. 10/070,954
Amdt. dated June 3, 2010
Reply to Advisory Action of March 10, 2010
```

y1|sulfony1|thien-2-y1)methy1|-3-methoxybenzamide; N-[(5-{[4-(1H-1,2,3-benzotriazol-1-y1)piperidin-1-

yl]sulfonyl}thien-2-yl)methyl]-2-hydroxybenzamide;

3-methoxy-N-[(5-{[4-(3-methoxyanilino)piperidin-1y1]sulfony1}thien-2-y1)methy1]benzamide;

N-{[5-({4-[3-(dimethylamino)anilino]piperidin-1-

yl}sulfonyl)thien-2-yl]methyl}-3-methoxybenzamide;

3-methoxy-N-[(5-{[4-(3-propylanilino)piperidin-1y1]sulfonyl}thien-2-y1)methyl]benzamide;

3-methoxy-N-{[5-({4-[3-

(methylsulfonyl)anilino]piperidin-1-yl}sulfonyl)thien-2vl]methyl}benzamide;

3-methoxy-N-{[5-({4-[3-

(methylsulfanyl)anilino]piperidin-1-yl}sulfonyl)thien-2yl]methyl}benzamide;

methyl 3-({1-[(5-{[(3-methoxybenzoyl)amino]-

methyl}thien-2-yl)sulfonyl]piperidin-4-yl}amino)-benzoate;

N-{[5-( $\{4-[3-(aminocarbony1)anilino\}piperidin-1-$ 

y1}sulfony1)thien-2~y1]methy1}-3-methoxybenzamide;

```
Appln. No. 10/070,954
Amdt. dated June 3, 2010
Reply to Advisory Action of March 10, 2010
```

```
3-methoxy-N-[(5-{[4-(2-methoxyanilino)piperidin-1-
yllsulfonyl}thien-2-vl)methvllbenzamide;
          N-({5-[(4-{3-nitroanilino}piperidin-1-
vl) sulfonvl|thien-2-vl}methvl)-3-methoxybenzamide:
          N-({5-[(4-{2-nitroanilino}piperidin-1-
yl) sulfonyl] thien-2-yl \methyl) -3-methoxybenzamide;
          N-{ [5-({4-[4-(aminocarbonyl)anilino]piperidin-1-
v1}sulfony1)thien-2-y1]methy1}-3-methoxybenzamide;
          N-[(5-{[4-(3-chloroanilino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide;
          N-[(5-{[4-(4-chloroanilino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide;
          3-methoxy-N-({5-[(4-{4-
[(trifluoromethyl)sulfonyl]anilino}piperidin-1-
vl) sulfonvl] thien-2-vl}methvl) benzamide:
          3-methoxv-N-({5-[(4-{3-
[(trifluoromethyl)sulfonyl]anilino}piperidin-1-
yl) sulfonyl] thien-2-yl}methyl) benzamide;
          N-({5-[(4-anilinopiperidin-1-yl)sulfonyl]thien-2-
v1}methv1)-3-methoxybenzamide:
          N-[(5-{[4-(4-hydroxyanilino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide;
          N-[(5-{[4-(2-hydroxyanilino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide;
```

```
Appln. No. 10/070,954
Amdt. dated June 3, 2010
Reply to Advisory Action of March 10, 2010
          3-methoxy-N-[(5-{[4-(pyrimidin-2-ylamino)piperidin-
1-yl]sulfonyl}thien-2-yl)methyl]benzamide;
          N-{[5-({4-[(3-aminopyridin-2-yl)amino]piperidin-1-
yl}sulfonyl)thien-2-yl]methyl}-3-methoxybenzamide;
          N-[(5-{[4-({3-nitropyridin-2-v1}amino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide:
          N-{[5-({4-[(2,2-dioxido-1,3-dihydro-2-benzethien-5-
yl) amino|piperidin-1 yl|sulfonyl) thien-2 yl|methyl|-3-
methoxybenzamide;
          N [(5 { [4 (2,3 dihydro-1H-inden 5-ylamino)piperidin-
1-yl]sulfonyl}thion-2-yl)methyl]-3-methoxybenzamide;
          3-methoxy-N-[(5-{[4-(2-propylanilino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]benzamide;
          3-methoxy-N-[(5-{[4-(4-propylanilino)piperidin-1-
yl] sulfonyl }thien-2-yl) methyl] benzamide;
          N-[(5-{[4-(3-tert-butylanilino)piperidin-1-
vl]sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide;
          3-methoxy-N-[(5-{[4-(2-phenylethyl)piperidin-1-
yl] sulfonyl}thien-2-yl) methyl] benzamide;
          N-[(5-{[4-(3-ethylanilino)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]-3-methoxybenzamide;
```

3 methoxy N [(5 [[4-(5,6,7,8 tetrahydronaphthalen 1-ylamino)piperidin 1 yl]sulfonyl)thien 2-yl)methyl]benzamide;

```
Appln. No. 10/070,954
Amdt. dated June 3, 2010
Reply to Advisory Action of March 10, 2010
```

```
N-[(5-{[4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]-2-oxo-1,2-dihydropyridine-3-
carboxamide:
          N-[(5-{[4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]-3,4-dihydroxybenzamide;
          N-[(5-{[4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-
yl]sulfonyl}thien-2-yl)methyl]pyridine-2-carboxamide;
          N-[(5-{[4-(hexyloxy)piperidin-1-yl]sulfonyl}thien-2-
yl) methyl] -3-methoxybenzamide;
          N-({5-[(4-heptanoylpiperidin-1-yl)sulfonyl]thien-2-
yl}methyl)-3-methoxybenzamide;
          4-chloro-N-[(5-{[4-(3-propylanilino)piperidin-1-
yl]sulfonyl}-2-furyl)methyl]benzamide;
          4-chloro-N-[(5-{[4-(3-chloroanilino)piperidin-1-
yl]sulfonyl}-2-furyl)methyl]benzamide;
          4-chloro-N-[(5-{[4-(3-methoxyanilino)piperidin-1-
yl]sulfonyl}-2-furyl)methyl]benzamide;
         4-chloro-N-{[5-({4-[3-
(trifluoromethyl)anilino]piperidin-1-yl}sulfonyl)-2-
furyl] methyl benzamide;
         4-chloro-N-{[5-({4-[3-
(dimethylamino)anilino|piperidin-1-vl\sulfonvl)-2-
furyl]methyl}benzamide;
```

4-chloro-N-{[5-({4-[3-

(methylsulfonyl) anilino]piperidin-1-yl}sulfonyl) -2-

furyl]methyl}benzamide;

4-chloro-N-{[5-({4-[3-

(methylsulfanyl)anilino]piperidin-1-yl}sulfonyl)-2-

furyl]methyl}benzamide;

methyl 3-({1-[(5-{[(4-chlorobenzoyl)amino]methyl}-2-

furyl)sulfonyl]piperidin-4-yl}amino)benzoate;

3-({1-[(5-{[(4-chlorobenzoyl)amino]methyl}-2-

furyl) sulfonyl] piperidin-4-yl amino) benzamide;

4-chloro-N-({5-[(4-{3-nitroanilino}piperidin-1-

yl)sulfonyl]-2-furyl}methyl)benzamide;

4-chloro-N-[(5- $\{[4-(2-methoxyanilino)piperidin-1-$ 

yl]sulfonyl}-2-furyl)methyl]benzamide;

4-chloro-N-({5-[(4-{2-nitroanilino}piperidin-1-

yl)sulfonyl]-2-furyl}methyl)benzamide;

4-chloro-N-[(5-{[4-(4-chloroanilino)piperidin-1-

yl]sulfonyl}-2-furyl)methyl]benzamide;

4-chloro-N-({5-[(4-{4-

[(trifluoromethyl)sulfonyl]anilino}piperidin-1-yl)sulfonyl]-2-

furvl}methvl)benzamide:

N-{[5-({4-[4-(aminocarbonyl)anilino]piperidin-1-

yl}sulfonyl)-2-furyl]methyl}-4-chlorobenzamide;

4-chloro-N-({5-[(4-{3-

 $\label{lem:condition} \mbox{[(trifluoromethyl)sulfonyl]anilino} \mbox{piperidin-1-yl)sulfonyl} -2-$ 

furyl}methyl)benzamide; and

N-({5-[(4-anilinopiperidin-1-yl)sulfonyl]-2-

furv1}methv1)-4-chlorobenzamide.

12. (Previously Presented) A sulfonamide compound according to claim 11, which is selected from the group consisting of:

4-chloro-N-[(5-{[4-(2,4-difluorobenzoyl)piperidin-1-y1]sulfonyl}thien-2-yl)methyl]benzamide;

N-( $\{5-[(4-anilinopiperidin-1-yl)sulfonyl]thien-2-$ 

yl}methyl)-4-chlorobenzamide;

N-[(5-{[4-(1H-1,2,3-benzotriazol-1-yl)piperidin-1-

yl]sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;

 $N-[(5-\{[4-(1H-benzimidazol-1-yl)piperidin-1-$ 

yl]sulfonyl}thien-2-yl)methyl]-4-chlorobenzamide;

4-chloro-N-{[5-({4-[3-propylanilino]piperidin-1-

yl}sulfonyl)thien-2-yl]methyl}benzamide;

4-chloro-N-[(5-{[4-(4-chloroanilino)piperidin-1-

yl]sulfonyl}thien-2-yl)methyl]benzamide;

4-nitro-N-[(5-{[4-(3-methoxyanilino)piperidin-1-

yllsulfonyl}thien-2-yl)methyl]benzamide;

nitrobenzoyl}amino)methyl]thien-2-yl}sulfonyl)piperidin-4yl]amino)benzoate;

N-[(5-{[4-(1H-1,2,3-benzotriazol-1-y1)piperidin-1-y1]sulfonyl}thien-2-y1)methyl]-2-hydroxybenzamide; and
N-({5-[(4-{2-nitroanilino}piperidin-1-y1)sulfonyl]thien-2-y1}methyl)-3-methoxybenzamide.

# 13-19. (Cancelled)

- 20. (Previously Presented) A pharmaceutical composition containing at least one sulfonamide compound according to claim 1 and a pharmaceutically acceptable carrier, diluent or excipient.
- 21. (Previously Presented) Process for the preparation of a sulfonamide compound according to claim 1, comprising reacting a sulfonyl chloride according to formula V

$$Ar^{1} \underset{O}{\parallel} N^{-}(CH_{2})_{n} Ar^{2} SO_{2}CI$$

with an amine according to formula VIII

# whereby

n is an integer of from 0 to 5,

n' is an integer of from 0 to 4,

 $R^6$  is selected from the group consisting of hydrogen, substituted or unsubstituted  $C_1\text{--}C_6$  alkyl, substituted or unsubstituted  $C_1\text{--}C_6$  alkoxy, OH, halogen, nitro, cyano, sulfonyl and oxo;

 $L^1$  and  $L^2$  are independently selected from the group consisting of hydrogen, substituted or unsubstituted  $C_2$ - $C_6$  alkenyl, substituted or unsubstituted  $C_2$ - $C_6$  alkenyl, and substituted or unsubstituted  $C_3$ - $C_6$  alkynyl; or  $L^1$  and  $L^2$  are independently selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted or unsubstituted or unsubstituted expl. c1- $C_6$  alkyl, heteroaryl-  $C_1$ - $C_6$  alkyl, substituted or unsubstituted cyclic  $C_4$ - $C_8$  alkyl optionally containing 1-3 heteroatoms and optionally fused with aryl or heteroaryl,  $-C(0)R^3$ ,  $-C(0)OR^3$ ,  $-C(0)-NR^3R^3$ ,  $-NR^3(C(0)R^3$ ,  $-NR^3(C(0)R^3$ ,  $-NR^3(C(0)R^3)$ ,

with  $R^3$  and  $R^{3'}$  being substituents independently selected from the group consisting of hydrogen, substituted or unsubstituted  $C_1$ - $C_6$  alkyl, substituted or unsubstituted aryl, substituted or unsubstituted or

unsubstituted aryl-  $C_1$ - $C_6$  alkyl and substituted or unsubstituted heteroaryl-  $C_1$ - $C_6$  alkyl;

said aryl or heteroaryl groups being optionally substituted  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl, amino, acylamino, aminocarbonyl,  $C_2$ - $C_6$  alkoxycarbonyl, aryl, carboxyl, cyano, halogen, hydroxy, nitro, sulfonyl, sulfoxy and  $C_1$ - $C_6$  thioalkoxy.

- \$22.\$ (Previously Presented) A process according to claim 21, wherein said sulfonyl chloride of formula V is obtained by
  - a) coupling an amine of formula II:

$$R^1HN$$
— $(CH_2)_n$ — $Ar^2$ 

with an acyl chloride of formula III:

to provide an amide of formula IV:

 $\label{eq:bound} b) \mbox{ sulfonating the amide of formula IV to provide}$  the sulfonyl chloride of formula V

$$Ar^{1} \underset{O}{\overset{}{\parallel}} \overset{N}{\overset{}{\parallel}} (CH_{2})_{n} \overset{}{\overset{}{\longrightarrow}} Ar^{2} \overset{}{\overset{}{\longrightarrow}} SO_{2}CI$$

Appln. No. 10/070,954 Amdt. dated June 3, 2010

Reply to Advisory Action of March 10, 2010

# 23-26. (Cancelled)

- 27. (Previously Presented) The sulfonamide compound according to claim 1 wherein n is an integer of from 1 to 3.
- 28. (Previously Presented) The sulfonamide compound according to claim 27 wherein n is 1.
- 29. (Previously Presented) The composition according to claim 2 wherein n is an integer of from 1 to 3.
- 30. (Previously Presented) The composition according to claim 29 wherein n is 1.
- 31. (Previously Presented) The composition according to claim 2 wherein n is 1 or 2.

### 32-34. (Cancelled)

35. (Previously Presented) The sulfonamide compound according to claim 5 wherein the  $C_1\text{-}C_6$  alkyl group is trihalomethyl.

## 36-41. (Cancelled)